Form 4 for BIAF bioAffinity Technologies, Inc.
Accepted 2022-12-02 00:00:00 ET · period of report 2022-08-31 · accession 0001493152-22-034366 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-02 | 2022-08-31 | BIAF | DIAMOND STUART | Dir | P - Purchase | — | +4,081 | 4,081 | New | — |
| DM | 2022-12-02 | 2022-08-31 | BIAF | DIAMOND STUART | Dir | P - Purchase | — | +8,162 | 4,081 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.007 | 2022-08-31 | P | A | 4,081 | — | 4,081 | D | — | — | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F2) The reported securities are included within 4,081 Units purchased by Mr. Diamond for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. |
| 2 | Derivative | Non-tradeable Warrants (right to buy) | 2022-08-31 | P | A | 4,081 | — | 4,081 | D | $7.66 · 2022-08-31 to 2027-08-31 | 4,081 Common Stock | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F2) The reported securities are included within 4,081 Units purchased by Mr. Diamond for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. |
| 3 | Derivative | Warrants (right to buy) | 2022-08-31 | P | A | 4,081 | — | 4,081 | D | $7.35 · 2022-08-31 to 2027-08-31 | 4,081 Common Stock | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F2) The reported securities are included within 4,081 Units purchased by Mr. Diamond for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. |